Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 10/20 | 0.98 |
| ▸ | CTNNB1 | P35222 | 10/20 | 0.98 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | SMO | Q99835 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20021894 | 0.91 | BCL9 (0.82) | BCL9CTNNB1SLC6A9MCHR1HTR2A | |
| SCHEMBL18165096 | 0.91 | BCL9 (0.98) | BCL9CTNNB1METMCHR1MEN1 | |
| SCHEMBL18152447 | 0.91 | BCL9 (0.81) | BCL9CTNNB1SLC6A9METMCHR1 | |
| SCHEMBL20021897 | 0.86 | BCL9 (0.89) | BCL9CTNNB1METMCHR1MEN1 | |
| SCHEMBL18165097 | 0.86 | CTNNB1 (0.98) | BCL9CTNNB1 | |
| SCHEMBL18165094 | 0.85 | BCL9 (0.98) | BCL9CTNNB1METHTR2A | |
| SCHEMBL18165095 | 0.84 | BCL9 (0.98) | BCL9CTNNB1METHTR2A | |
| SCHEMBL20021886 | 0.84 | BCL9 (0.84) | BCL9CTNNB1METKDRHTR2A | |
| SCHEMBL18165153 | 0.81 | BCL9 (0.98) | BCL9CTNNB1HTR2A | |
| SCHEMBL18152329 | 0.81 | BCL9 (0.79) | BCL9CTNNB1METMCHR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180092866-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2018-04-05 | — | — | US | disclosed |
| WO-2016168524-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092866-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | BCL9, BCL9L, BCL3 | BCL9 1/4885CTNNB1 4/4885SLC6A9 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.